SSR-504,734
SSR-504,734
SSR-504,734 is a pharmacological compound that acts as a selective antagonist of the glycine transporter 1 (GlyT1). It has been studied for its potential therapeutic effects in various neurological and psychiatric disorders, particularly those involving cognitive dysfunction and negative symptoms, such as schizophrenia.
Pharmacology[edit | edit source]
SSR-504,734 functions by inhibiting the reuptake of glycine, an important co-agonist at the NMDA receptor (N-methyl-D-aspartate receptor). By blocking GlyT1, SSR-504,734 increases the availability of glycine in the synaptic cleft, thereby enhancing NMDA receptor function. This mechanism is thought to improve cognitive processes and alleviate negative symptoms associated with NMDA receptor hypofunction.
Mechanism of Action[edit | edit source]
The primary action of SSR-504,734 is the inhibition of the glycine transporter 1 (GlyT1), which is responsible for the reuptake of glycine from the synaptic cleft back into the presynaptic neuron. By inhibiting GlyT1, SSR-504,734 increases extracellular glycine levels, facilitating greater activation of NMDA receptors. This is particularly relevant in brain regions such as the prefrontal cortex and hippocampus, which are involved in cognitive functions and are often impaired in disorders like schizophrenia.
Clinical Research[edit | edit source]
Research on SSR-504,734 has primarily focused on its potential use in treating schizophrenia. Studies have shown that SSR-504,734 can improve cognitive deficits and negative symptoms in animal models of schizophrenia. However, clinical trials in humans are necessary to fully establish its efficacy and safety profile.
Potential Therapeutic Applications[edit | edit source]
- Schizophrenia: SSR-504,734 may help address cognitive impairments and negative symptoms, which are not adequately treated by current antipsychotic medications.
- Cognitive Disorders: By enhancing NMDA receptor function, SSR-504,734 could potentially be beneficial in other cognitive disorders, although more research is needed.
Safety and Side Effects[edit | edit source]
As with any pharmacological agent, the safety profile of SSR-504,734 is a critical consideration. Preclinical studies have not indicated significant adverse effects, but comprehensive clinical trials are required to assess its safety in humans.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
